Picton Mahoney Asset Management Avidity Biosciences, Inc. Transaction History
Picton Mahoney Asset Management
- $5.81 Billion
- Q1 2025
A detailed history of Picton Mahoney Asset Management transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Picton Mahoney Asset Management holds 56 shares of RNA stock, worth $1,807. This represents 0.0% of its overall portfolio holdings.
Number of Shares
56Holding current value
$1,807% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding RNA
# of Institutions
253Shares Held
110MCall Options Held
517KPut Options Held
717K-
Price T Rowe Associates Inc Baltimore, MD11.3MShares$366 Million0.04% of portfolio
-
Wellington Management Group LLP Boston, MA9.68MShares$313 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.24MShares$298 Million0.01% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$278 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY7.93MShares$256 Million3.76% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.68B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...